Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Deferasirox
Drug ID BADD_D00594
Description Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Indications and Usage For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Marketing Status approved; investigational
ATC Code V03AC03
DrugBank ID DB01609
KEGG ID D03669
MeSH ID D000077588
PubChem ID 214348
TTD Drug ID D0Q5UQ
NDC Product Code 49706-2103; 59285-010; 66039-871; 31722-030; 43598-852; 45963-454; 45963-456; 67877-552; 69238-1703; 69452-161; 69539-200; 70700-271; 70771-1410; 70771-1471; 58032-2017; 0078-0468; 0078-0469; 31722-013; 43598-854; 69238-1488; 69452-159; 69539-023; 46708-410; 57664-768; 62332-324; 62756-568; 69539-021; 69539-073; 69539-199; 62332-412; 67877-550; 67877-553; 69097-391; 69097-560; 69539-022; 70771-1472; 65727-037; 0078-0655; 42806-371; 43598-851; 67877-554; 68462-495; 68462-496; 69097-392; 70710-1012; 62512-0078; 0078-0470; 0078-0654; 0078-0720; 31722-029; 43598-856; 46708-411; 46708-412; 69097-393; 69238-1486; 69539-303; 70710-1276; 72205-176; 14501-0049; 63278-1070; 65085-0063; 66022-0301; 0078-0656; 31722-031; 43598-855; 57664-769; 62332-325; 62756-569; 69539-075; 70710-1011; 72205-075; 72647-372; 74436-0323; 31722-012; 43598-853; 62332-326; 62332-411; 62756-570; 68462-494; 69097-570; 69238-1487; 69238-1702; 69238-1704; 70710-1013; 70771-1411; 70771-1473; 0591-3853; 72647-371; 0591-2961; 11722-040; 53104-7713; 59651-419; 0078-0727; 42806-372; 46708-324; 46708-325; 57664-770; 67877-549; 69539-074; 70700-270; 72205-076; 65015-738; 0078-0713; 31722-011; 42806-373; 45963-455; 46708-326; 62332-410; 67877-551; 69097-550; 69452-160; 70700-269; 70710-1275; 70710-1277; 70771-1409; 72647-373; 65372-1164
UNII V8G4MOF2V9
Synonyms Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade
Chemical Information
Molecular Formula C21H15N3O4
CAS Registry Number 201530-41-8
SMILES C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Terminal state08.01.03.0790.001859%Not Available
Neck mass15.03.02.0070.001239%Not Available
Hepatic siderosis14.13.03.005; 09.01.10.0080.004585%Not Available
Acute chest syndrome24.03.08.006; 22.06.03.004; 01.04.02.0040.006815%Not Available
Leukaemic infiltration pulmonary16.01.03.007; 01.10.03.007; 22.08.01.0160.001239%Not Available
Growth hormone deficiency05.03.02.0040.001239%Not Available
Hepatic mass09.01.08.0150.001239%Not Available
Cell death14.11.02.005; 08.03.03.0030.001239%Not Available
Nephrogenic anaemia01.03.04.001; 20.01.01.0070.001239%Not Available
Carnitine deficiency14.08.04.0220.001239%Not Available
Leukaemia recurrent16.01.03.005; 01.10.03.005--Not Available
Acute lymphocytic leukaemia recurrent16.01.01.003; 01.10.01.0030.001859%Not Available
Graft versus host disease in liver09.01.07.033; 12.02.09.029; 10.02.01.0600.001239%Not Available
Apparent death08.01.03.0620.001859%Not Available
Oncologic complication16.32.03.0250.001239%Not Available
Pure white cell aplasia01.03.03.0130.001239%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.004337%Not Available
Eye colour change06.06.06.0080.002726%Not Available
Internal haemorrhage24.07.01.0720.001859%Not Available
Primary myelofibrosis16.21.03.008; 01.13.03.0080.001239%Not Available
Alloimmunisation18.04.18.002; 10.02.04.003; 01.06.01.0060.001239%Not Available
Bone marrow transplant rejection10.02.03.008; 01.05.01.0230.001239%Not Available
Cardiac iron overload14.13.03.008; 12.02.08.009; 02.04.01.0140.005204%Not Available
Dilated cardiomyopathy02.04.01.0170.001239%Not Available
Disease complication08.01.03.0870.006815%Not Available
Gait inability17.02.05.069; 08.01.02.0110.010532%Not Available
Hepatic cytolysis09.01.07.0360.001239%Not Available
Hernia perforation08.01.04.0060.001239%Not Available
Hypersensitivity myocarditis02.04.03.006; 10.01.03.0550.002478%Not Available
Illness08.01.03.091--Not Available
The 17th Page    First    Pre   17 18    Next   Last    Total 18 Pages